OMass Therapeutics Overview

  • Founded
  • 2016

Founded
  • Status
  • Private

  • Employees
  • 53

Employees
  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $100M

  • Investors
  • 8

OMass Therapeutics General Information

Description

Developer of a structural mass spectrometry technology platform designed to discover novel medicines. The company's platform offers access to native mass spectrometry without having to establish sophisticated instrumentation and expertise in-house, as well as provides a way to study complex protein assemblies and their interactions with other biological molecules, enabling biotechnology and pharmaceutical clients to tackle challenging drug targets and biotherapeutics, within a dynamic and collaborative framework.

Contact Information

Website
www.omass.com
Formerly Known As
OMass Technologies
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Discovery Tools (Healthcare)
Primary Office
  • Schrodinger Building Oxford Science Park
  • Oxford OX4 4GE
  • England, United Kingdom
+44 01865 000000

OMass Therapeutics Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

OMass Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC (Series B) 28-Apr-2022 $100M 00000 Completed Pre-Clinical Trials
4. Later Stage VC (Series A) 13-Feb-2020 000.00 000.00 000.00 Completed Pre-Clinical Trials
3. Early Stage VC (Series A) 26-Jun-2018 000.00 000.00 000.00 Completed Pre-Clinical Trials
2. Grant 01-Mar-2018 $645K $3.07M Completed Pre-Clinical Trials
1. Seed Round 29-Mar-2016 $3.07M $3.07M 00.000 Completed Startup
To view OMass Therapeutics’s complete valuation and funding history, request access »

OMass Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 00,000,000 00.000000 00.00 00.00 00 00.00 00.000
A Ordinary 0,000,000 00.000000 00.00 00.00 00 00.00 00.000
Ordinary 1,165,513 $0.001303 $1.3 $1.3 1x $1.3 5.41%
To view OMass Therapeutics’s complete cap table history, request access »

OMass Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of a structural mass spectrometry technology platform designed to discover novel medicines. The company's plat
Drug Discovery
Oxford, United Kingdom
53 As of 2022
00000
00000000000 00000

000000

liquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillu
0000 000000000
South San Francisco, CA
00 As of 0000
00000
0.000 0000-00-00
000000&0 00000

000000

aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. E
0000000000000
Brisbane, CA
000 As of 0000
00000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

OMass Therapeutics Competitors (14)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Amunix Pharmaceuticals Formerly PE-Backed South San Francisco, CA 00 00000 000000&0 00000
0000000 0000000000 Formerly VC-backed Brisbane, CA 000 00000 000000000 00000
00000000000 000000 Formerly VC-backed Newark, CA 000 00000 00000000 00000
000000 Formerly VC-backed Redwood City, CA 000 00000 00000000 00000
00000000 Venture Capital-Backed Vienna, Austria 00.000 0000000000 00.000
You’re viewing 5 of 14 competitors. Get the full list »

OMass Therapeutics Executive Team (8)

Name Title Board Seat Contact Info
Ali Jazayeri Ph.D Chief Scientific Officer
Hsin-Yung Yen Ph.D Co-Founder & Director of Biology
Idlir Liko Ph.D Co-Founder & Director of Technology
Miguel Silva Strategy Director
Jonathan Hopper Ph.D Co-Founder & Vice President, Platforms
You’re viewing 5 of 8 executive team members. Get the full list »

OMass Therapeutics Board Members (15)

Name Representing Role Since
Carol Robinson OMass Therapeutics Co-Founder, Scientific Advisor & Board Member 000 0000
Christopher Ashton Ph.D Syncona Board Member 000 0000
Diana Bernstein Ph.D Northpond Ventures Board Member 000 0000
Edward Hodgkin Ph.D Syncona Chairman 000 0000
Jonathan Montagu Self Board Member 000 0000
You’re viewing 5 of 15 board members. Get the full list »

OMass Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

OMass Therapeutics Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
GV Corporate Venture Capital Minority 000 0000 000000 0
Northpond Ventures Venture Capital Minority 000 0000 000000 0
Sanofi Ventures Corporate Venture Capital Minority 000 0000 000000 0
Syncona Venture Capital Minority 000 0000 000000 0
University of Oxford Corporation Minority 000 0000 000000 0
You’re viewing 5 of 8 investors. Get the full list »

OMass Therapeutics Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000000 0 25-Feb-2020 0000000000 Biotechnology 00000000
To view OMass Therapeutics’s complete acquisitions history, request access »